Extra treatments to boost immunotherapy for advanced melanoma or liver cancer
Treatments studied
Part of Cancer, Digestive system, Skin clinical trials.
This study tests additional therapies given alongside standard immunotherapy for advanced melanoma or liver cancer. The goal is to see if adding these treatments can make the immunotherapy work better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have advanced melanoma or liver cancer that has not spread beyond the liver or has spread to other parts of the body.
- You must be planning to start a standard first-line immunotherapy drug, such as a PD-1/PD-L1 inhibitor.
- You must be 18 or older and able to care for yourself (ECOG score 0–2).
- You must not have had chemotherapy or other systemic cancer treatment for advanced disease before. Prior surgery or radiation is okay, as long as it was at least 6 months ago.
- You must not have an autoimmune disease that requires daily steroids (10 mg or more of prednisone) or other immune-suppressing medicine.
- You must not be taking beta-blockers (heart or blood pressure drugs) or certain allergy medicines (H1 blockers).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a precise, targeted form of radiation (called SBRT) to standard immunotherapy (atezolizumab and bevacizumab) can help people with advanced liver cancer that has spread to the blood vessels or outside the liver. You may be asked to participate in one of two treatment groups to see which approach works better.
This trial tests a combination of local treatments (like TACE or HAIC) with bevacizumab and an immunotherapy drug (PD-1/L1 inhibitor) for advanced liver cancer. It may be an option if you haven't had systemic therapy before or if your previous treatment stopped working.
This trial tests a combination of two immunotherapy drugs (durvalumab and tremelimumab) plus a pain reliever (celecoxib) for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug combination works better than standard treatments.
This trial tests a combination of liver-directed chemotherapy (HEPZATO KIT) with a new immunotherapy called Opdualag for people whose melanoma has spread to the liver and who have not had many prior treatments.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
Hear when a new Advanced Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.